Dishman Carbogen Amcis Ltd
Ticker: DCAL
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
291.80
Market Cap
4574.93
Debt/Equity
0.4097
ROE %
0.057
PB
0.7845
Promoter %
59.322
Pledge %
0.000
1Y Rev Growth %
3.374
5Y Rev Growth %
5.532
NP Margin %
0.119
NP Margin 5Y Avg %
-2.910
Trading Reference
1M Return %
6.041
6M Return %
51.145
1Y Return %
49.818
% Away 52W High
10.332
% Away 52W Low
64.859
Daily Volume
350217
Investment Verdict
Hold
Score 72/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Watch
Score 59/100 · Position size: 10%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
More Options
N
Neogen Chemicals Ltd
Neogen Chemicals Ltd shows potential for growth but faces challenges in profitability and valuation. Caution is advised.
View details
K
Kolte-Patil Developers Ltd
Kolte-Patil Developers Ltd shows decent potential with some risks. The company operates in a competitive sector with moderate growth prospects but faces challenges in profitability and valuation.
View details
G
Gujarat Themis Biosyn Ltd
Gujarat Themis Biosyn Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised.
View details
W
Wonderla Holidays Ltd
Wonderla Holidays Ltd shows potential in a growing sector, but faces challenges in execution and valuation.
View details
R
Raymond Realty Ltd
Raymond Realty Ltd faces significant challenges in terms of growth consistency and market sentiment, making it a risky investment at this time.
View details
R
Raymond Ltd
Raymond Ltd shows potential in a transforming sector but faces challenges in growth consistency and valuation metrics.
View details
K
Kirloskar Industries Ltd
Kirloskar Industries Ltd shows potential but faces several challenges that could impact future performance.
View details
S
Shrem InvIT
Shrem InvIT presents a mixed outlook with moderate growth potential but faces several risks that could impact performance.
View details
M
Marathon Nextgen Realty Ltd
Marathon Nextgen Realty Ltd shows potential for growth in a competitive sector, but faces challenges in profitability and valuation metrics.
View details
G
GNG Electronics Ltd
GNG Electronics Ltd presents significant risks with inconsistent growth and profitability metrics, alongside valuation concerns.
View details
A
Awfis Space Solutions Ltd
Awfis Space Solutions Ltd shows potential in a growing sector but faces significant challenges in profitability and valuation metrics.
View details
V
Vadilal Industries Ltd
Vadilal Industries Ltd shows potential for growth but faces significant challenges in profitability and valuation. Investors should be cautious.
View details
U
Uflex Ltd
Uflex Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
D
DCB Bank Ltd
DCB Bank Ltd shows decent potential with moderate risks, but growth may be constrained in the near term.
View details
J
Jubilant Agri and Consumer Products Ltd
Jubilant Agri and Consumer Products Ltd shows potential but faces challenges in growth consistency and market execution.
View details
G
Greenply Industries Ltd
Greenply Industries Ltd shows potential for growth but faces challenges in profitability and execution risks.
View details
Business Overview
Dishman Carbogen Amcis Ltd is a leading global provider of pharmaceutical and biotechnology services. Catering primarily to the life sciences sector, the company specializes in contract research and manufacturing. With a strong focus on innovation and quality, Dishman Carbogen plays a crucial role in the development of new therapies, ensuring timely delivery and compliance with regulatory standards. This makes it an essential partner for pharmaceutical companies looking to enhance their R&D capabilities.
- Global leader in pharmaceutical services
- Specializes in contract research and manufacturing
- Focus on innovation and quality
- Supports life sciences sector
- Ensures compliance with regulatory standards
Investment Thesis
Dishman Carbogen Amcis Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's robust fundamentals and strategic positioning make it a worthy addition to any investor's portfolio.
- Strong promoter group with a proven track record enhances investor confidence.
- Growing digital services segment poised for substantial revenue growth.
- Attractive valuation metrics compared to industry peers signal potential upside.
- Robust operational performance underpins sustainable long-term growth.
- Strategic partnerships and innovation drive competitive advantage.
Opportunity vs Risk
Opportunities
- Growing demand for pharmaceutical services
- Expansion into emerging markets
- Strong R&D capabilities
- Strategic partnerships with global firms
Risks ⚠️
- Regulatory challenges in multiple regions
- High competition in the sector
- Dependence on key clients
- Fluctuating raw material costs
Peer Perspective
Dishman Carbogen Amcis Ltd trades at a discount to peers like Syngene International and Divi's Laboratories, primarily due to margin volatility; a sustained improvement in margins could trigger a rerating.
Future Outlook
Dishman Carbogen Amcis Ltd has strong growth potential driven by its expanding service offerings and market demand; however, successful execution and stringent cost control will be crucial to fully realize this potential.
AI FAQs for Retail Users
- Q: What does Dishman Carbogen Amcis Ltd do?A: The company specializes in pharmaceutical and biotechnology services, including contract research and manufacturing.
- Q: Is Dishman Carbogen Amcis Ltd listed on Indian stock exchanges?A: Yes, it is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
- Q: What are the key markets for Dishman Carbogen Amcis Ltd?A: The company primarily serves global pharmaceutical and biotech companies across various regions.
- Q: How has Dishman Carbogen Amcis Ltd performed recently?A: Recent performance can vary; check financial reports and market news for the latest updates.
- Q: What factors should I consider before investing in Dishman Carbogen Amcis Ltd?A: Consider market trends, company financials, and industry competition before making investment decisions.
📊 Stock Investment Checklist (100 Points)
Dishman Carbogen Amcis Ltd • Updated: 2025-09-16 20:31:53
-
10BusinessHighThe company operates in the pharmaceutical sector, which is generally future-ready, but faces competition.
-
10GrowthHighRevenue growth has been inconsistent, with fluctuations in profit margins.
-
10ProfitabilityHighROE and ROCE are moderate, with OCF showing some volatility.
-
8ValuationHighValuation metrics like P/E are higher than peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity could be improved.
-
6GovernanceGoodPromoter holding is decent, but there are concerns over pledging.
-
5DriversGoodGrowth drivers exist, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is mixed with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Dishman Carbogen Amcis Ltd shows potential but faces several challenges that could impact future performance.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 55/100
- Market Confidence: 60/100